[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338513-105":59,"doc-detail-338513-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-of-an-efficient-nupr1-inhibitor-with-anticancer-activity","Development of an efficient NUPR1 inhibitor with anticancer activity","","Pancreatic cancer is highly lethal with limited curative options. Prior work produced ZZW-115, a NUPR1-targeting candidate whose clinical translation was restricted by potential hERG cardiotoxicity due to interaction with the human Ether-à-go-go-Related Gene potassium channel. High-throughput screening of 10,000 compounds identified AJO14 as a lead binding NUPR1 without hERG affinity, inducing apoptosis, necroptosis, and parthanatos via mitochondrial catastrophe and ATP reduction. This hyperPARylation-driven effect was reversed by Olaparib, and AJO14 reduced tumors in xenografted mice in a dose-dependent manner.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-an-efficient-nupr1-inhibitor-with-anticancer-activity/338513/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-an-efficient-nupr1-inhibitor-with-anticancer-activity/338513.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why was ZZW-115 limited for clinical translation?","Question",{"text":112,"@type":113},"Clinical translation was hindered by potential cardiotoxicity stemming from interaction with the hERG potassium channel.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was AJO14 identified and what is its key pharmacological advantage?",{"text":117,"@type":113},"A high-throughput screen of 10,000 compounds identified AJO14 as a lead that binds NUPR1 while lacking favorable affinity toward hERG, reducing cardiotoxicity concerns.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism drives AJO14-induced cancer cell death?",{"text":121,"@type":113},"AJO14 triggers apoptosis, necroptosis, and parthanatos through mitochondrial catastrophe and decreased ATP production, mediated by hyperPARylation, which can be reversed by the PARP inhibitor Olaparib.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338513,1790218683,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDevelopment of an efficient NUPR1 inhibitor with anticancer activity  \nXi Liu1,14, Ana Jimenez-Alesanco2,14, Zexian Li3, Bruno Rizzuti2,4, José L. Neira2,5, Matías Estaras1, Ling Peng6, Eduardo Chuluyan7,8, Juan Garona9,10, Florencia Gottardo9,10, Adrián Velazquez-Campoy2,11,12,13, Yi Xia3, Olga Abian2,11,12,13,  \nPatricia Santofimia-Castaño1􀀍 & Juan Iovanna1,9,10􀀍  \nPancreatic cancer is highly lethal and has limited treatment options available. Our team had previously developed ZZW-115, a promising drug candidate that targets the nuclear protein 1 (NUPR1), which is involved in pancreatic cancer development and progression. However, clinical translation of ZZW-115 was hindered due to potential cardiotoxicity caused by its interaction with the human Ether-à-go-go-Related Gene (hERG) potassium channel. To address this, we have performed a highthroughput screening of 10,000 compounds from the HitFinder Chemical Library, and identified AJO14 as a lead compound that binds to NUPR1, without having favorable affinity towards hERG. AJO14 induced cell death through apoptosis, necroptosis, and parthanatos (induced by the poly-ADP ribose polymerase (PARP) overactivation), driven by mitochondrial catastrophe and decreased ATP production. This process seemed to be mediated by the hyperPARylation (an excessive modification of proteins by PARP, leading to cellular dysfunction), as it could be reversed by Olaparib, a PARP inhibitor. In xenografted mice, AJO14 demonstrated a dose-dependent tumor reduction activity. Furthermore, we attempted to improve the anti-cancer properties of AJO14 by molecular modification of the lead compound. Among the 51 candidates obtained and tested, 8 compounds exhibited a significant increase in efficacy and have been retained for further studies, especially LZX-2-73. These AJO14-derived compounds offer potent NUPR1 inhibition for pancreatic cancer treatment, without cardiotoxicity concerns.  \nAbbreviations  \nhERG Human Ether-à-go-go-Related Gene  \nPARP Poly-ADP ribose polymerase  \nPDAC Pancreatic ductal adenocarcinoma  \nTSA Thermal-shift assay  \nLB Luria–Bertani broth  \nDMSO Dimethyl sulfoxide  \nANS Extrinsic fluorescent probe 8-anilino-1-naphthalene sulfonic acid  \n1Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR7258, Aix Marseille Université and Institut Paoli Calmettes, Parc Scientifique etTechnologique de Luminy, Equipe labéliséeLigue Nationale contre le cancer, 163 Avenue de Luminy, 13288 Marseille, France. 2Instituto de Biocomputación y Física de Sistemas Complejos (BIFI), 50018 Zaragoza, Spain. 3Chongqing Key Lab oratory of Natural Product Synthesis and Drug Research, School ofPharmaceutical Sciences, Chongqing University, No.55 Daxuecheng South Road, Chongqing 401331, People’s Republic of China. 4CNR NANOTEC, SS Rende (CS), Department of Physics, University of Calabria, Via P. Bucci, Cubo 31 C, 87036 Rende, Italy. 5IDIBE, Universidad Miguel Hernández, Edificio Torregaitán, Avda. del Ferrocarril s/n, 03202 Elche, Alicante, Spain. 6Aix Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille, UMR7325, Parc Scientifique et Technologique de Luminy, Equipe labélisée Ligue Nationale contre le cancer, 163 Avenue de Luminy, 13288 Marseille, France. 7Center for Pharmacological and Botanical Studies, Faculty of Medicine, National Council for Scientific and Technical Research, Buenos Aires University, C1121ABG Buenos Aires, Argentina. 8Department of Microbiology, Parasitology and Immunology, Faculty of Medicine, Buenos Aires University, C1121ABG Buenos Aires, Argentina. 9Hospital de Alta Complejidad El Cruce, Florencio Varela, Buenos Aires, Argentina. 10University Arturo Jauretche, Florencio Varela, Buenos Aires, Argentina. 11Aragon Institute for Health Research (IIS Aragon), Zaragoza, Spain. 12Centro de Investigación Biomédica en Red en el Área Temática de Enfe rmedadesHepáticas y","cbCaicwZCyjuovCj","https://ap.wps.com/l/cbCaicwZCyjuovCj","pdf",10504095,"English","# Background\n## Epidemiology and clinical challenges in pancreatic cancer\n## Current standard treatments and limitations\n# NUPR1 targeting strategy\n## ZZW-115 and the hERG cardiotoxicity issue\n# Discovery of AJO14\n## High-throughput screening from HitFinder Chemical Library\n## Binding specificity to NUPR1 and reduced hERG affinity\n# Mechanism and preclinical efficacy\n## Cell death pathways and mitochondrial catastrophe\n## hyperPARylation and rescue by Olaparib\n## Xenograft tumor reduction\n# Lead optimization\n## Molecular modifications and candidate selection","[{\"question\":\"Why was ZZW-115 limited for clinical translation?\",\"answer\":\"Clinical translation was hindered by potential cardiotoxicity stemming from interaction with the hERG potassium channel.\"},{\"question\":\"How was AJO14 identified and what is its key pharmacological advantage?\",\"answer\":\"A high-throughput screen of 10,000 compounds identified AJO14 as a lead that binds NUPR1 while lacking favorable affinity toward hERG, reducing cardiotoxicity concerns.\"},{\"question\":\"What mechanism drives AJO14-induced cancer cell death?\",\"answer\":\"AJO14 triggers apoptosis, necroptosis, and parthanatos through mitochondrial catastrophe and decreased ATP production, mediated by hyperPARylation, which can be reversed by the PARP inhibitor Olaparib.\"}]","Development of an efficient NUPR1 inhibitor with anticancer activity | PDF",1790023982,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cdddd68e3ebaacef1a95ac904f35527.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42fffd122cdd68a11c503af4dcd43fe1.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c942f7a8020c3de4efd506aeffd9b5cf.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37fc20c418ac02bb6c5cf05edf384a9f.webp",980,1287]